As previously reported, Anixa and OntoChem have identified four compounds that could disrupt the function of a viral enzyme called an endoribonuclease (also known as Non-Structural Protein-15, or NSP-15).
The potential NSP-15 inhibitors have been synthesized and are in the process of being tested in biological assays, the results of which should be available in a few weeks or sooner.
The candidate inhibitors of Mpro are being synthesized, a process that is anticipated to take three to four weeks, and then they will be tested in biological assays.
Based on initial identification of the Mpro scaffold compound, Anixa and OntoChem have created a new in silico library of analog compounds that will be evaluated through additional in silico screening to choose which additional compounds may be synthesized and evaluated in biological assays.
Anixa is a biotechnology company developing a number of programmes addressing cancer and infectious disease.
Anixa's therapeutic portfolio includes a cancer immunotherapy programme which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.
The company's vaccine portfolio consists of a technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialisation.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer